EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Unraveling the role of galectin-3 in cardiac pathology and physiology

Ignacio M Seropian, Pablo Cassaglia, Verónica Miksztowicz, Germán E González

Frontiers in Physiology · 18.12.2023 · 14

DOI: 10.3389/fphys.2023.1304735 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Physiology, online erschienen am 18.12.2023. Verfasst von Ignacio M Seropian und 3 weiteren Autor:innen. Beteiligte Einrichtung: Laboratorio de Patología Cardiovascular Experimental e Hipertensión Arterial, Instituto de Investigaciones Biomédicas (UCA-CONICET), Facultad de Cien…. Die Arbeit wurde bisher 60-mal zitiert (Crossref) und nennt 133 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Galectin-3 (Gal-3) is a carbohydrate-binding protein with multiple functions. Gal-3 regulates cell growth, proliferation, and apoptosis by orchestrating cell-cell and cell-matrix interactions. It is implicated in the development and progression of cardiovascular disease, and its expression is increased in patients with heart failure. In atherosclerosis, Gal-3 promotes monocyte recruitment to the arterial wall boosting inflammation and atheroma. In acute myocardial infarction (AMI), the expression of Gal-3 increases in infarcted and remote zones from the beginning of AMI, and plays a critical role in macrophage infiltration, differentiation to M1 phenotype, inflammation and interstitial fibrosis through collagen synthesis. Genetic deficiency of Gal-3 delays wound healing, impairs cardiac remodeling and function after AMI. On the contrary, Gal-3 deficiency shows opposite results with improved remodeling and function in other cardiomyopathies and in hypertension. Pharmacologic inhibition with non-selective inhibitors is also protective in cardiac disease. Finally, we recently showed that Gal-3 participates in normal aging. However, genetic absence of Gal-3 in aged mice exacerbates pathological hypertrophy and increases fibrosis, as opposed to reduced fibrosis shown in cardiac disease. Despite some gaps in understanding its precise mechanisms of action, Gal-3 represents a potential therapeutic target for the treatment of cardiovascular diseases and the management of cardiac aging. In this review, we summarize the current knowledge regarding the role of Gal-3 in the pathophysiology of heart failure, atherosclerosis, hypertension, myocarditis, and ischemic heart disease. Furthermore, we describe the physiological role of Gal-3 in cardiac aging.

Schlagwörter

Stichwörter der Autor:innen

atherosclerosiscardiac agingcardiac remodelingcardiovascular pathologygalectin 3healinginflammationmyocardial infarction

Autor:innen und Institutionen

  • Laboratorio de Patología Cardiovascular Experimental e Hipertensión Arterial, Instituto de Investigaciones Biomédicas (UCA-CONICET), Facultad de Ciencias Médicas Universidad Católica Argentina, Buenos Aires, Argentina.
  • Servicio de Hemodinamia, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
  • Departamento de Patología, Instituto de Salud Comunitaria, Universidad Nacional de Hurlingham, Buenos Aires, Argentina.

Zitieren

APA

Seropian, I. M., Cassaglia, P., Miksztowicz, V., & González, G. E. (2023). Unraveling the role of galectin-3 in cardiac pathology and physiology. Frontiers in Physiology, 14. https://doi.org/10.3389/fphys.2023.1304735

Vancouver

Seropian IM, Cassaglia P, Miksztowicz V, González GE. Unraveling the role of galectin-3 in cardiac pathology and physiology. Frontiers in Physiology. 2023;14. doi:10.3389/fphys.2023.1304735

BibTeX
@article{Seropian2023,
  author = {Seropian, Ignacio M and Cassaglia, Pablo and Miksztowicz, Verónica and González, Germán E},
  title = {Unraveling the role of galectin-3 in cardiac pathology and physiology},
  journal = {Frontiers in Physiology},
  year = {2023},
  volume = {14},
  doi = {10.3389/fphys.2023.1304735}
}
Kostenlos starten →